In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Leap Therapeutics Inc (LPTX), with a price target of $12.50. The company’s shares closed yesterday at $2.71, equals to its 52-week low of $2.71.
Ramakanth commented:
“We maintain our Buy rating of Leap Therapeutics and our 12-month price target of $12.50 per diluted share. We derive our price target based on a risk-adjusted NPV analysis of projected DKN-01 and TRX518 revenues through 2030 assuming a 12% discount rate and 2% terminal growth rate. We derive an rNPV of $638M for the products and add in cash and cash equivalents of $23.2M to arrive at a 12-month price target of $12.47 per diluted share, which we round to $12.50.”
According to TipRanks.com, Ramakanth is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -4.4% and a 31.9% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Collplant Holdings Ltd.
Currently, the analyst consensus on Leap Therapeutics Inc is a Moderate Buy with an average price target of $12.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $10.25 and a one-year low of $2.71. Currently, Leap Therapeutics Inc has an average volume of 76.07K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company. It invests in great science and targeted research will rapidly translate molecules into high impact therapeutics. The firm’s pipeline is built upon identifying and developing translational-stage molecules in the areas of cell signaling and immuno-oncology.
